Skip to content

Investigating Lysosomal Storage Diseases in Minority Groups

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02120235
Enrollment
20000
Registered
2014-04-22
Start date
2014-02-28
Completion date
2018-12-31
Last updated
2017-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fabry Disease, Gaucher Disease, Lysosomal Storage Disorders, Niemann-Pick Disease, Pompe Disease

Keywords

Lysosomal storage disorders, LSD, Gaucher disease, Fabry disease, Pompe disease, Niemann-Pick disease

Brief summary

Although lysosomal storage disorders, such as Fabry disease, Gaucher disease, and Pompe disease, represent serious challenges in the healthcare system, no study has yet investigated the prevalence of these diseases in the US. Frequently, patients show progressive worsening of symptoms for several years before they get diagnosed. Since many of these diseases can be managed therapeutically, it is important to identify and treat patients in order to avoid organ damage. The investigators aim to undertake a screening study that identifies undiagnosed patients with lysosomal storage disorders and determine the prevalence of these diseases with special focus on underrepresented minority groups.

Interventions

None listed

Sponsors

O & O Alpan LLC
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
1 Days to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject is greater than or equal to 1 day of age and less than or equal to 100 years of age * Subject is managed by a physician in the Washington, D.C metro area * Subject is getting blood work as part of standard clinical care and there is at least 60 uL blood remained in a tube after all clinical tests were run

Exclusion criteria

* Absolute contraindication for blood drawing * Subject cannot be traced back by the referring physician upon a positive screening result

Design outcomes

Primary

MeasureTime frame
Number of patients identified with lysosomal storage disorders2 years

Countries

United States

Contacts

Primary ContactOzlem Goker-Alpan, M.D.
ogokeralpan@oandoalpan.com571-308-1900

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026